Report by the ACNP Task Force on response and remission in major depressive disorder

Area of Science:

• Psychiatry
• Clinical Psychology
• Neuroscience

Background:

• Standardized definitions for treatment outcomes in major depressive disorder (MDD) are lacking.
• Current outcome measures like 'response' may be less reliable than 'remission' due to reliance on single baseline measures.
• The American College of Neuropsychopharmacology (ACNP) convened a task force to address these conceptual gaps.

Purpose of the Study:

• To propose standardized definitions for remission, recovery, relapse, and recurrence in the context of MDD.
• To provide clear, clinically relevant endpoints for both researchers and clinicians treating depression.
• To establish criteria for remission based on sustained minimal symptom status.

Main Methods:

• The ACNP Task Force synthesized clinical experience and logical consistency to develop definitions.
• Recommendations are based on maintaining minimal symptom status for a defined period (3 consecutive weeks).
• Criteria differentiate between remission, recovery, relapse, and recurrence based on duration and absence of specific symptoms.

Main Results:

• Remission is defined as maintaining minimal symptom status for 3 consecutive weeks.
• Recovery is defined as achieving remission and maintaining it for at least 4 months without relapse.
• Relapse is defined as the loss of remission, and recurrence as the loss of recovery.

Conclusions:

• Remission is a valid and clinically significant endpoint for MDD treatment, associated with better function and prognosis.
• Symptom ratings covering all nine criterion domains of a major depressive episode are preferred for accurate remission assessment.
• Empirical research is needed to validate these proposed definitions and their clinical utility.